CETO3^®: the new Omega

CETO3^® is a natural fish oil ingredient which contains a high level of Cetoleic acid (Omega-11) with Omega-3 (EPA and DHA). CETO3^® is derived from North Atlantic herring. High levels of Omega-11 is uniquely found in North Atlantic pelagic fish. Omega-11 have proven to increase the human body’s own production of EPA/DHA.

CET03® points of difference

• Contains Cetoleic acid (Omega-11) and Omega-3 EPA/DHA
• Cetoleic acid is the main fatty acid in North Atlantic herring
• Cetoleic acid stimulates and increases the body’s own production of EPA/DHA
• Single source fish Omega-3 ingredient
• No fishy smell, taste or unpleasant reflux – can be taken as both liquid and capsule\
• Immediate processing: from fresh fish to oil takes as little as 30 minutes
• Human grade production process without any solvent or chemicals
• Low on pollutants as pelagic fish swim neither up in the surface or bottom of the ocean
• CETO3^® is harvested and produced in Norway
• Low carbon footprint

Equal effectiveness of omega-3 polyunsaturated fatty acids (n-3 PUFAs) from CET03 and fish oil in elevating the omega-3 index

The nature of the source of omega-3 PUFAs can affect bioavailability of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). A new source of omega-3 is CET03^® (Omega-11 and Omega-3), unlike Fish oil (FOil), contains high levels of monounsaturated fatty acid Cetoleic acid (Omega-11).

This study aimed to examine the effect of CET03^® in healthy subjects on the omega-3 PUFA status over 12 weeks and to compare it with the same length of intervention with fish oil (FOil). The Omega-3 Index, a measurement of the DHA and EPA content of red blood cells compared to the total percentage content of all other identifiable fatty acids, was used to quantify the omega-3 status.

In this randomised double-blind study, 30 participants were randomly allocated to either the:

- CET03^® group: DHA+EPA dose: 400 mg/day per 2 capsules, n=14
- FOil group: DHA+EPA dose: 600 mg/day/2 capsules, n=16

Following completion of the 12 week intervention, the increase in Omega-3 Index was comparable between both groups

- CET03^®: 5.73 ± 1.38%; p<0.00001
- FOil: 6.24 ± 1.35%; p<0.0003

The results of this study demonstrate that the effect of CET03^® on the Omega-3 Index increase over 12 weeks is comparable to FOil. Given that CET03^® typically contains 200 mg of EPA/DHA per 1000 mg capsule compared to 300 mg EPA/DHA in the fish oil capsules used in this trial, it would appear from the results of this pilot study, on a pro-rata dose equivalence, that CET03^® might deliver a 50% improvement in the Omega-3 Index.

Reference: Wakeman M. Equal effectiveness of omega-3 polyunsaturated fatty acids (n-3 PUFAs) from CET03 and fish oil in elevating the omega-3 index: A 12-week randomized placebo controlled parallel study. International Journal of Scientific Research. 2024;13(1)

For more information, contact Craig Fallshaw at craig@cmgrouponline.com.au